{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:15:32Z","timestamp":1783091732729,"version":"3.54.6"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,18]]},"DOI":"10.7759\/cureus.88216","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T09:58:42Z","timestamp":1752832722000},"source":"Crossref","is-referenced-by-count":3,"title":["Revisiting Metformin in the Management of Polycystic Ovary Syndrome (PCOS)"],"prefix":"10.7759","author":[{"given":"Venkata Madhavi Latha","family":"Telagarapu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka  Devi","family":"Nallamothu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Nikhila","family":"Telagarapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikar Raja Chowdary","family":"Nalluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saispoorthy","family":"Nathani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandu Priya","family":"Kopani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Yarraguntla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriharika","family":"Vyasalapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2024.1576","article-title":"Global prevalence of overweight and obesity in children and adolescents. A systematic review and meta-analysis","volume":"178","author":"Zhang X","year":"2024","unstructured":"Zhang X, Liu J, Ni Y, et al.. Global prevalence of overweight and obesity in children and adolescents. A systematic review and meta-analysis. JAMA Pediatr. 2024, 178:800-13. 10.1001\/jamapediatrics.2024.1576","journal-title":"JAMA Pediatr"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2022.2052","article-title":"Trends in obesity prevalence among children and adolescents aged 2 to 19 years in the US from 2011 to 2020","volume":"176","author":"Hu K","year":"2022","unstructured":"Hu K, Staiano AE. Trends in obesity prevalence among children and adolescents aged 2 to 19 years in the US from 2011 to 2020. JAMA Pediatr. 2022, 176:1037-9. 10.1001\/jamapediatrics.2022.2052","journal-title":"JAMA Pediatr"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3310\/hta19430","article-title":"The use of measures of obesity in childhood for predicting obesity and the development of obesity-related diseases in adulthood: a systematic review and meta-analysis","volume":"19","author":"Simmonds M","year":"2015","unstructured":"Simmonds M, Burch J, Llewellyn A, et al.. The use of measures of obesity in childhood for predicting obesity and the development of obesity-related diseases in adulthood: a systematic review and meta-analysis. Health Technol Assess. 2015, 19:10.3310\/hta19430","journal-title":"Health Technol Assess"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2023-0168","article-title":"Causes of obesity: a review","volume":"23","author":"Masood B","year":"2023","unstructured":"Masood B, Moorthy M. Causes of obesity: a review. Clin Med (Lond). 2023, 23:284-91. 10.7861\/clinmed.2023-0168","journal-title":"Clin Med (Lond)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108549","article-title":"Obesity and its comorbidities, current treatment options and future perspectives: challenging bariatric surgery?","volume":"251","author":"Kloock S","year":"2023","unstructured":"Kloock S, Ziegler CG, Dischinger U. Obesity and its comorbidities, current treatment options and future perspectives: challenging bariatric surgery?. Pharmacol Ther. 2023, 251:108549. 10.1016\/j.pharmthera.2023.108549","journal-title":"Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2008.247","article-title":"WHO recognition of the global obesity epidemic","volume":"32 Suppl 7","author":"James WP","year":"2008","unstructured":"James WP. WHO recognition of the global obesity epidemic. Int J Obes (Lond). 2008, 32 Suppl 7:S120-6. 10.1038\/ijo.2008.247","journal-title":"Int J Obes (Lond)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j477","article-title":"Adiposity and cancer at major anatomical sites: umbrella review of the literature","volume":"356","author":"Kyrgiou M","year":"2017","unstructured":"Kyrgiou M, Kalliala I, Markozannes G, et al.. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ. 2017, 356:j477. 10.1136\/bmj.j477","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa285","article-title":"Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists","volume":"105","author":"Cena H","year":"2020","unstructured":"Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab. 2020, 105:e2695-709. 10.1210\/clinem\/dgaa285","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1179558119874042","article-title":"Obesity and polycystic ovary syndrome: implications for pathogenesis and novel management strategies","volume":"13","author":"Barber TM","year":"2019","unstructured":"Barber TM, Hanson P, Weickert MO, Franks S. Obesity and polycystic ovary syndrome: implications for pathogenesis and novel management strategies. Clin Med Insights Reprod Health. 2019, 13:10.1177\/1179558119874042","journal-title":"Clin Med Insights Reprod Health"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldac007","article-title":"Why are women with polycystic ovary syndrome obese?","volume":"143","author":"Barber TM","year":"2022","unstructured":"Barber TM. Why are women with polycystic ovary syndrome obese?. Br Med Bull. 2022, 143:4-15. 10.1093\/bmb\/ldac007","journal-title":"Br Med Bull"},{"key":"ref11","article-title":"Obesity: definition, comorbidities, causes, and burden","volume":"22","author":"Apovian CM","year":"2016","unstructured":"Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016, 22:s176-85.","journal-title":"Am J Manag Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9240569","article-title":"Association of insulin resistance and elevated androgen levels with polycystic ovarian syndrome (PCOS): a review of literature","volume":"2022","author":"Xu Y","year":"2022","unstructured":"Xu Y, Qiao J. Association of insulin resistance and elevated androgen levels with polycystic ovarian syndrome (PCOS): a review of literature. J Healthc Eng. 2022, 2022:9240569. 10.1155\/2022\/9240569","journal-title":"J Healthc Eng"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-022-01091-0","article-title":"Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment","volume":"16","author":"Zhao H","year":"2023","unstructured":"Zhao H, Zhang J, Cheng X, Nie X, He B. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res. 2023, 16:9. 10.1186\/s13048-022-01091-0","journal-title":"J Ovarian Res"},{"key":"ref14","article-title":"Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome","volume":"6","author":"Yildirim B","year":"2003","unstructured":"Yildirim B, Sabir N, Kaleli B. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2003, 6:1358-64.","journal-title":"Fertil Steril"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-019-00335-3","article-title":"Metformin: mechanisms in human obesity and weight loss","volume":"8","author":"Yerevanian A","year":"2019","unstructured":"Yerevanian A, Soukas AA. Metformin: mechanisms in human obesity and weight loss. Curr Obes Rep. 2019, 8:156-64. 10.1007\/s13679-019-00335-3","journal-title":"Curr Obes Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaa023","article-title":"Cellular and molecular mechanisms of metformin action","volume":"42","author":"LaMoia TE","year":"2021","unstructured":"LaMoia TE, Shulman GI. Cellular and molecular mechanisms of metformin action. Endocr Rev. 2021, 42:77-96. 10.1210\/endrev\/bnaa023","journal-title":"Endocr Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00833-4","article-title":"Metformin: update on mechanisms of action and repurposing potential","volume":"19","author":"Foretz M","year":"2023","unstructured":"Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023, 19:460-76. 10.1038\/s41574-023-00833-4","journal-title":"Nat Rev Endocrinol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12328","article-title":"New mechanisms of metformin action: focusing on mitochondria and the gut","volume":"6","author":"Hur KY","year":"2015","unstructured":"Hur KY, Lee MS. New mechanisms of metformin action: focusing on mitochondria and the gut. J Diabetes Investig. 2015, 6:600-9. 10.1111\/jdi.12328","journal-title":"J Diabetes Investig"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.1016\/S1262-3636(03)72785-2","article-title":"Reducing insulin resistance with metformin: the evidence today","volume":"29","author":"Giannarelli R","year":"2003","unstructured":"Giannarelli R, Coppelli A, Del Prato S. Reducing insulin resistance with metformin: the evidence today. Diabetes Metab. 2003, 29:6S28-6S35.","journal-title":"Diabetes Metab"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1210\/en.2012-1145","article-title":"Metformin inhibits human androgen production by regulating steroidogenic enzymes HSD3B2 and CYP17A1 and complex I activity of the respiratory chain","volume":"153","author":"Hirsch A","year":"2012","unstructured":"Hirsch A, Hahn D, Kempn\u00e1 P, Hofer G, Nuoffer JM, Mullis PE, Fl\u00fcck CE. Metformin inhibits human androgen production by regulating steroidogenic enzymes HSD3B2 and CYP17A1 and complex I activity of the respiratory chain. Endocrinology. 2012, 153:4354-66. 10.1210\/en.2012-1145","journal-title":"Endocrinology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608293350902","article-title":"Decreases in ovarian cytochrome P450c17\u03b1 activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome","volume":"335","author":"Nestler JE","year":"1996","unstructured":"Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17\u03b1 activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 1996, 335:617-23. 10.1056\/NEJM199608293350902","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03459.x","article-title":"The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis","volume":"70","author":"Barba M","year":"2009","unstructured":"Barba M, Sch\u00fcnemann HJ, Sperati F, Akl EA, Musicco F, Guyatt G, Muti P. The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2009, 70:661-70. 10.1111\/j.1365-2265.2008.03459.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmh010","article-title":"The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest","volume":"10","author":"Jonard S","year":"2004","unstructured":"Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update. 2004, 10:107-17. 10.1093\/humupd\/dmh010","journal-title":"Hum Reprod Update"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2846","article-title":"Insulin and insulin-like growth factor stimulation of vascular endothelial growth factor production by luteinized granulosa cells: comparison between polycystic ovarian syndrome (PCOS) and non-PCOS women","volume":"92","author":"Stanek MB","year":"2007","unstructured":"Stanek MB, Borman SM, Molskness TA, Larson JM, Stouffer RL, Patton PE. Insulin and insulin-like growth factor stimulation of vascular endothelial growth factor production by luteinized granulosa cells: comparison between polycystic ovarian syndrome (PCOS) and non-PCOS women. J Clin Endocrinol Metab. 2007, 92:2726-33. 10.1210\/jc.2006-2846","journal-title":"J Clin Endocrinol Metab"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1210\/en.2014-1765","article-title":"Metformin regulates ovarian angiogenesis and follicular development in a female polycystic ovary syndrome rat model","volume":"156","author":"Di Pietro M","year":"2015","unstructured":"Di Pietro M, Parborell F, Irusta G, et al.. Metformin regulates ovarian angiogenesis and follicular development in a female polycystic ovary syndrome rat model. Endocrinology. 2015, 156:1453-63. 10.1210\/en.2014-1765","journal-title":"Endocrinology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000095","article-title":"Effects of metformin on weight loss: potential mechanisms","volume":"21","author":"Malin SK","year":"2014","unstructured":"Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014, 21:323-9. 10.1097\/MED.0000000000000095","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2023.101805","article-title":"Effects of metformin on the gut microbiota: a\u00a0systematic review","volume":"77","author":"Pavlo Petakh","year":"2023","unstructured":"Pavlo Petakh, Kamyshna I, Kamyshnyi A. Effects of metformin on the gut microbiota: a\u00a0systematic review. Mol Metab. 2023, 77:101805. 10.1016\/j.molmet.2023.101805","journal-title":"Mol Metab"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dem271","article-title":"Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial","volume":"22","author":"Trolle B","year":"2007","unstructured":"Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum Reprod. 2007, 22:2967-73. 10.1093\/humrep\/dem271","journal-title":"Hum Reprod"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013505","article-title":"Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome","volume":"12","author":"Sharpe A","year":"2019","unstructured":"Sharpe A, Morley LC, Tang T, Norman RJ, Balen AH. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019, 12:CD013505. 10.1002\/14651858.CD013505","journal-title":"Cochrane Database Syst Rev"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2016.12.001","article-title":"Ovulation induction by metformin among obese versus non-obese women with polycystic ovary syndrome","volume":"25","author":"Al-Ruthia YS","year":"2017","unstructured":"Al-Ruthia YS, Al-Mandeel H, AlSanawi H, Mansy W, AlGasem R, AlMutairi L. Ovulation induction by metformin among obese versus non-obese women with polycystic ovary syndrome. Saudi Pharm J. 2017, 25:795-800. 10.1016\/j.jsps.2016.12.001","journal-title":"Saudi Pharm J"},{"key":"ref31","doi-asserted-by":"crossref","DOI":"10.51248\/.v42i1.875","article-title":"Effect of metformin therapy on lipid profile in obese and non-obese women with polycystic ovarian syndrome (PCOS)","volume":"42","author":"Swathi A","year":"2022","unstructured":"Swathi A, Vijayalakshmi, Reddy IY. Effect of metformin therapy on lipid profile in obese and non-obese women with polycystic ovarian syndrome (PCOS). Biomedicine. 2022, 42:134-7.","journal-title":"Biomedicine"},{"key":"ref32","article-title":"Effect of administration of metformin on lipid profile in patients with polycystic ovary syndrome after six months of treatment","volume":"2","author":"Mehandiratta R","year":"2016","unstructured":"Mehandiratta R, Jindal P, Takkar V, Kapila PT, Kapila R. Effect of administration of metformin on lipid profile in patients with polycystic ovary syndrome after six months of treatment.  Int J Med Res Prof . 2016, 2:66-9.","journal-title":"Int J Med Res Prof"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmv025","article-title":"Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis","volume":"21","author":"Naderpoor N","year":"2015","unstructured":"Naderpoor N, Shorakae S, de Courten B, Misso ML, Moran LJ, Teede HJ. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update. 2015, 21:560-74. 10.1093\/humupd\/dmv025","journal-title":"Hum Reprod Update"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64776-w","article-title":"Effects of lifestyle modification in polycystic ovary syndrome compared to metformin only or metformin addition: a systematic review and meta-analysis","volume":"10","author":"Kim CH","year":"2020","unstructured":"Kim CH, Chon SJ, Lee SH. Effects of lifestyle modification in polycystic ovary syndrome compared to metformin only or metformin addition: a systematic review and meta-analysis. Sci Rep. 2020, 10:7802. 10.1038\/s41598-020-64776-w","journal-title":"Sci Rep"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13041056","article-title":"The role of sodium-glucose cotransporter-2 inhibitors in the treatment of polycystic ovary syndrome: a review","volume":"13","author":"Porth R","year":"2024","unstructured":"Porth R, Oelerich K, Sivanandy MS. The role of sodium-glucose cotransporter-2 inhibitors in the treatment of polycystic ovary syndrome: a review. J Clin Med. 2024, 13:1056. 10.3390\/jcm13041056","journal-title":"J Clin Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14583","article-title":"Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: a randomized, open-label, noninferiority trial","volume":"24","author":"Cai M","year":"2022","unstructured":"Cai M, Shao X, Xing F, et al.. Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: a randomized, open-label, noninferiority trial. Diabetes Obes Metab. 2022, 24:312-20. 10.1111\/dom.14583","journal-title":"Diabetes Obes Metab"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13968","article-title":"Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study","volume":"90","author":"Javed Z","year":"2019","unstructured":"Javed Z, Papageorgiou M, Deshmukh H, et al.. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study. Clin Endocrinol (Oxf). 2019, 90:805-13. 10.1111\/cen.13968","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14013","article-title":"Effect of the combined oral contraceptive pill and\/or metformin in the management of polycystic ovary syndrome: a systematic review with meta-analyses","volume":"91","author":"Teede H","year":"2019","unstructured":"Teede H, Tassone EC, Piltonen T, et al.. Effect of the combined oral contraceptive pill and\/or metformin in the management of polycystic ovary syndrome: a systematic review with meta-analyses. Clin Endocrinol (Oxf). 2019, 91:479-89. 10.1111\/cen.14013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005552.pub3","article-title":"Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome","volume":"8","author":"Fraison E","year":"2020","unstructured":"Fraison E, Kostova E, Moran LJ, Bilal S, Ee CC, Venetis C, Costello MF. Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome. Cochrane Database Syst Rev. 2020, 8:CD005552. 10.1002\/14651858.CD005552.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref40","doi-asserted-by":"crossref","DOI":"10.1016\/j.mefs.2014.10.003","article-title":"Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 month follow up period","volume":"20","author":"El Maghraby HA","year":"2015","unstructured":"El Maghraby HA, Nafee T, Guiziry D, Elnashar A. Randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 month follow up period. Middle East Fertil Soc J. 2015, 20:131-7.","journal-title":"Middle East Fertil Soc J"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-023-01055-z","article-title":"Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"21","author":"Greff D","year":"2023","unstructured":"Greff D, Juh\u00e1sz AE, V\u00e1ncsa S, et al.. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2023, 21:10. 10.1186\/s12958-023-01055-z","journal-title":"Reprod Biol Endocrinol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13304","article-title":"Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study","volume":"86","author":"Tagliaferri V","year":"2017","unstructured":"Tagliaferri V, Romualdi D, Immediata V, De Cicco S, Di Florio C, Lanzone A, Guido M. Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clin Endocrinol (Oxf). 2017, 86:725-30. 10.1111\/cen.13304","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12854","article-title":"Understanding and overcoming metformin gastrointestinal intolerance","volume":"19","author":"Bonnet F","year":"2017","unstructured":"Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab. 2017, 19:473-81. 10.1111\/dom.12854","journal-title":"Diabetes Obes Metab"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v12.i7.916","article-title":"Long-term metformin therapy and vitamin B12 deficiency: an association to bear in mind","volume":"12","author":"Infante M","year":"2021","unstructured":"Infante M, Leoni M, Caprio M, Fabbri A. Long-term metformin therapy and vitamin B12 deficiency: an association to bear in mind. World J Diabetes. 2021, 12:916-31. 10.4239\/wjd.v12.i7.916","journal-title":"World J Diabetes"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/389350-revisiting-metformin-in-the-management-of-polycystic-ovary-syndrome-pcos","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T09:58:43Z","timestamp":1752832723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/389350-revisiting-metformin-in-the-management-of-polycystic-ovary-syndrome-pcos"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.88216","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,18]]}}}